<DOC>
	<DOCNO>NCT01910311</DOCNO>
	<brief_summary>The purpose study look effect multiple dose rifampicin single dose baricitinib look safety tolerability drug . Side effect document . The study last approximately 31 day first dose end study .</brief_summary>
	<brief_title>A Study Baricitinib Rifampicin Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Are overtly healthy male female Male participant : Agree use 2 reliable method birth control female partner childbearing potential study least 3 month follow last dose study drug Female participant : Women childbearing potential due surgical sterilization ( least 3 month surgical hysterectomy , bilateral oophorectomy without hysterectomy , bilateral tubal occlusion/ligation ) confirm medical history , menopause . Menopausal woman woman spontaneous amenorrhea least 12 month , induce medical condition anorexia nervosa take medication amenorrhea induce amenorrhea ( e.g . oral contraceptive , hormone , gonadotropin release hormone , antiestrogens , selective estrogen receptor modulators , chemotherapy ) . Menopausal status confirm folliclestimulating hormone ( FSH ) level great 40 international unit per liter ( IU/L ) screening ( unless participant take hormone replacement therapy [ HRT ] ) Have body weight ≥60 kilogram ( kg ) time screen Have clinical laboratory test result within normal reference range Have normal renal function Have normal blood pressure pulse rate ( supine position ) Have venous access sufficient allow blood sample Are currently enrol , complete , discontinue within last 90 day clinical trial involve study drug , concurrently enrol type medical research judge scientifically medically compatible study Have previously complete withdrawn study study investigate baricitinib , previously receive study drug Have know allergy baricitinib , rifampicin , related compound , component baricitinib rifampicin formulation , history significant atopy Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder Have average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior first dose completion safety followup assessment ( Day 18 ± 1 ; 1 unit = 12 oz 360 milliliter ( mL ) beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Have history , opinion investigator , excessive methylxanthine use within previous 6 month , great ( &gt; ) 6 cup coffee ( equivalent ) per day Currently smoke 10 cigarette per day unable abide Clinical Research Unit ( CRU ) restriction Are unwilling refrain use soft contact lenses start second treatment period final followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>